Neuropathologic substrate of mild cognitive impairment
- PMID: 16401735
- DOI: 10.1001/archneur.63.1.38
Neuropathologic substrate of mild cognitive impairment
Abstract
Objective: To define the neuropathologic findings in amnestic mild cognitive impairment (MCI) and early Alzheimer disease (EAD).
Methods: The mean numbers of diffuse plaques, neuritic plaques (NPs), and neurofibrillary tangles (NFTs) in 4 neocortical regions and 4 ventromedial temporal lobe regions were counted in 10 patients with amnestic MCI and compared with the mean numbers in 23 normal control subjects and 10 patients with EAD, and then were compared with memory performance. All of the controls and patients were followed longitudinally.
Results: Patients with MCI showed no significant difference (P>.05) in the number of diffuse plaques from that in normal controls or patients with EAD. In patients with MCI, the number of NPs was significantly elevated in all 4 neocortical regions and amygdala compared with controls (P<.01 to <.001). There were no significant differences (P>.05) in the number of NPs between MCI and EAD cerebral cortex, but significant increases were present for NPs in EAD amygdala and subiculum compared with MCI (P<.01). In patients with MCI compared with controls, the only significant increase in NFTs in the neocortex was in the parietal lobe. However, the number of NFTs was significantly elevated in MCI in all 4 ventromedial temporal lobe structures compared with controls (P<.01 to <.001). In comparing MCI with EAD, there were significant increases in NFTs in EAD in frontal and temporal lobes, amygdala, and subiculum (P<.01). The numbers of NPs and NFTs were significantly elevated in all of the neocortical regions and ventromedial temporal lobe regions in patients with EAD compared with controls (P<.001). Memory function was significantly correlated with NFTs in CA1 of the hippocampus (P<.01) and the entorhinal cortex (P<.05).
Conclusions: In patients with amnestic MCI who were followed longitudinally, the early changes of Alzheimer disease were present. The NFTs were slightly more prominent than beta-amyloid peptide deposition in the progression from normal to MCI to EAD. Ventromedial temporal lobe NFTs probably represent the substrate for memory decline in MCI. From a neuropathologic perspective, it appears that amnestic MCI is, in reality, EAD.
Comment in
-
Mild cognitive impairment is early-stage Alzheimer disease: time to revise diagnostic criteria.Arch Neurol. 2006 Jan;63(1):15-6. doi: 10.1001/archneur.63.1.15. Arch Neurol. 2006. PMID: 16401731 No abstract available.
Similar articles
-
Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.Arch Neurol. 2003 May;60(5):729-36. doi: 10.1001/archneur.60.5.729. Arch Neurol. 2003. PMID: 12756137
-
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.Brain. 2006 Nov;129(Pt 11):3035-41. doi: 10.1093/brain/awl269. Epub 2006 Sep 29. Brain. 2006. PMID: 17012293
-
Structural correlates of cognitive deficits in a selected group of patients with Alzheimer's disease.Neuropsychiatry Neuropsychol Behav Neurol. 1998 Oct;11(4):184-90. Neuropsychiatry Neuropsychol Behav Neurol. 1998. PMID: 9845409
-
The neuropathological changes associated with normal brain aging.Histol Histopathol. 1996 Oct;11(4):1075-88. Histol Histopathol. 1996. PMID: 8930649 Review.
-
[Concept and clinical presentation of mild cognitive impairment].Brain Nerve. 2010 Jul;62(7):719-25. Brain Nerve. 2010. PMID: 20675876 Review. Japanese.
Cited by
-
Enrichment and stratification for predementia Alzheimer disease clinical trials.PLoS One. 2012;7(10):e47739. doi: 10.1371/journal.pone.0047739. Epub 2012 Oct 17. PLoS One. 2012. PMID: 23082203 Free PMC article.
-
Mild cognitive impairment in Parkinson disease: heterogenous mechanisms.J Neural Transm (Vienna). 2013 Jan;120(1):157-67. doi: 10.1007/s00702-012-0771-5. Epub 2012 Feb 18. J Neural Transm (Vienna). 2013. PMID: 22350538 Review.
-
Mild Cognitive Impairment: Structural, Metabolical, and Neurophysiological Evidence of a Novel EEG Biomarker.Front Neurol. 2015 Jul 6;6:152. doi: 10.3389/fneur.2015.00152. eCollection 2015. Front Neurol. 2015. PMID: 26217299 Free PMC article. Review.
-
Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.Neurotox Res. 2011 Feb;19(2):211-34. doi: 10.1007/s12640-010-9190-2. Neurotox Res. 2011. PMID: 20393891 Review.
-
Key Mechanisms and Potential Implications of Hericium erinaceus in NLRP3 Inflammasome Activation by Reactive Oxygen Species during Alzheimer's Disease.Antioxidants (Basel). 2021 Oct 22;10(11):1664. doi: 10.3390/antiox10111664. Antioxidants (Basel). 2021. PMID: 34829535 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous